The findings also demonstrate the potential beneficial effects of calcium channel blockers on cSVD imaging markers and cholesteryl ester transfer protein inhibitors, lipoprotein lipase enhancement and gastric inhibitory polypeptide receptor obesity-targeted drugs on LS. The gene discussed is GIPR; the disease is obesity due to melanocortin 4 receptor deficiency.